Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Cloudflare | Pfizer | Amkor Technology | |
|---|---|---|---|
| Moat rating | wide The band is earned by a measured share gap on a hard-to-rebuild asset, not asserted. W3Techs' 17 September 2026 survey (w3techs.com/technologies/overview/proxy) puts Cloudflare in front of 25.8% of all websites, an 85.0% share of the reverse-proxy market, against Amazon CloudFront at 5.5%, Fastly at 3.0% and Akamai at 2.1% - roughly fifteen times the nearest rival. The FY2025 10-K filed 2026-02-26 describes what a challenger would have to reproduce to contest that: a network that 'spans more than 330 cities in over 125 countries worldwide and interconnects with over 13,000 networks globally', architected to 'run every service on every server in every city' - capacity and peering accumulated city by city over a decade, not bought in a quarter. The position has been monetised without margin decay: SEC XBRL fundamentals on this site show GAAP gross margin inside a 74.5-78.7% band in every fiscal year from FY2017 to FY2025 while revenue grew from $134.9M to $2,167.9M, and Cloudflare's Q4/FY2025 results release of 2026-02-10 (cloudflare.com/press/press-releases/2026/cloudflare-announces-fourth-quarter-and-fiscal-year-2025-financial-results/) reports remaining performance obligations up 48% and new annual contract value up nearly 50% year over year. What stops this being a certainty rather than a judgement: the dominant share sits in application services, while SASE and developer compute are contested by vendors the 10-K itself concedes hold 'substantially greater financial, technical, and other resources.' | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. | narrow The FY2025 10-K describes a real but bounded edge. On the plus side, Amkor says "Our scale and geographic diversity allow us to qualify production at multiple sites, optimize asset utilization and absorb large orders that require quick turnaround." It also says "Amkor has built long-standing relationships with most of the world's leading semiconductor companies over the last five decades." And it says that "in line with industry practice, customers usually require us to pass a lengthy and rigorous qualification process that may take several months". It falls short of wide because the same filing calls the market "highly competitive", names ASE Technology, JCET Group and Powertech Technology as rivals, and says Amkor faces Asian providers "including companies with significantly greater processing capacity, financial resources". It also says foundries "substantially larger than us" have expanded into packaging and test, and that IDMs and foundries "may decide to shift some or all of their outsourced packaging and test services to internally sourced capacity". Returns are thin: MD&A gross margin was 14.0% in 2025, 14.8% in 2024 and 14.5% in 2023, with a 7.0% operating margin in 2025. |
| Moat type | cost scale The FY2025 10-K states the mechanism outright, and it is a unit-cost curve rather than a user-to-user network: 'We have chosen to utilize this idle capacity to create a free tier of service which has generated substantial global scale for us. In turn, this scale makes us attractive partners for Internet Service Providers (ISPs) globally, which reduces our co-location and bandwidth costs. As our network grows, these dynamics become even more powerful.' The same section explains why the curve applies to every line rather than one: the architecture lets Cloudflare 'deploy standard, commodity hardware' and run 'every service on every server in every city', so a new product reaches 330+ cities at near-zero incremental capital. That is what lets the filing claim Workers is offered 'at prices that are highly competitive with public cloud vendors' while FY2025 GAAP gross margin still printed 74.5%. Switching costs (traffic routed through Cloudflare, DNS delegated to it) and threat-intelligence feedback from aggregate traffic sit on top, but the filing-stated primary source is cost falling as the network grows. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. | cost scale Part of the 10-K's cost/scale case applies to the whole industry, not to Amkor alone. It says packaging and test service providers "can typically use their assets to support a broad range of customers and multiple end markets, potentially generating more efficient use of their production assets and a more cost-effective solution", in contrast to IDMs running their own lines. The Amkor-specific support is its footprint, which it calls "a key differentiator", and its purchasing scale: "By leveraging our purchasing power and operational expertise, we look to secure favorable pricing and supply agreements for materials and equipment, further enhancing our competitive position." It adds: "We also negotiate worldwide pricing agreements with our major suppliers to take advantage of the scale of our operations." Against other OSATs the scale edge is limited, because Item 1A concedes Asian rivals "including companies with significantly greater processing capacity, financial resources". Multi-month customer qualification and long customer relationships add a secondary switching-cost element. IP is not the source: "Although our patents are an important element of our intellectual property strategy, we are not materially dependent on any one patent or any one technology." |
| Leadership | clear leader Leadership is measured, not inferred. W3Techs on 2026-09-17 records an 85.0% reverse-proxy market share against 5.5% for Amazon CloudFront and 2.1% for Akamai, and makes Cloudflare the largest authoritative-DNS provider at 18.5% of all websites versus 9.9% for the next-placed GoDaddy Group. The FY2025 10-K reports the enterprise side moving the same way - 4,298 large customers at 2025 year-end against 3,497 a year earlier and 2,756 in 2023 - and the Q4/FY2025 results release (cloudflare.com/press/press-releases/2026/cloudflare-announces-fourth-quarter-and-fiscal-year-2025-financial-results/) cites the largest annual contract value deal in company history at about $42.5M per year. The band is for the application-services core the share data covers; in SASE and in serverless compute Cloudflare is a challenger to larger incumbents, and no independent placement naming Cloudflare in those markets was obtained for this profile. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' | co leader The FY2025 10-K opens: "Amkor is the world's largest U.S. headquartered outsourced semiconductor assembly and test service provider (“OSAT”) and is a global leader in outsourced semiconductor packaging and test services." It claims to be a global leader, not the leader, and its one superlative is limited to U.S.-headquartered providers. It names ASE Technology, JCET Group and Powertech Technology as rivals. It concedes Asian competitors "including companies with significantly greater processing capacity, financial resources". About the key competitive factors it lists, it says only "We believe we are competitive in these areas." |
| Pricing power | moderate Evidence cuts both ways, which is why this is not the top band. For it: GAAP gross margin has never left a 74.5-78.7% band across FY2017-FY2025 (SEC XBRL fundamentals on this site) even as revenue compounded 16x, and the Q4/FY2025 results release (cloudflare.com/press/press-releases/2026/cloudflare-announces-fourth-quarter-and-fiscal-year-2025-financial-results/) shows customers committing more rather than less - RPO +48% year over year and new ACV up nearly 50%. Against it: FY2025's 74.5% is the lowest reading in that nine-year series, a large permanent free tier anchors the entry price, the 10-K positions Workers 'at prices that are highly competitive with public cloud vendors', and the competition risk factor warns that larger rivals can 'sell products and services with which we compete at zero or negative margins, offer fee waivers and reductions or other economic and non-economic concessions', with competitive pressure that 'may result in price reductions, fewer subscriptions, reduced revenue and gross margin'. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. | weak Item 1A of the FY2025 10-K says "Prices for packaging and test services have generally declined over time, and sometimes prices can change significantly in relatively short periods of time." It also says "We expect downward pressure on average selling prices for our packaging and test services to continue in the future, and this pressure may intensify during downturns in business." MD&A gross margin was 14.0% in 2025 against 14.8% in 2024 and 14.5% in 2023. The notes say the longer test-equipment depreciation life "reduced depreciation expense by approximately $59 million in 2024". Materials alone were 55.2% of 2025 net sales. The customer base is concentrated: the ten largest customers were 72% of 2025 net sales, with Apple at 29.8% and Qualcomm at 11.1%, and the filing flags "a reduction in orders or decrease in price from a significant customer" as a risk. |
| Summary | Cloudflare sells security, performance and connectivity as services delivered from one global anycast network rather than from boxes at a customer's edge. The FY2025 10-K frames the market as a consolidation away from enterprises that 'string together a diverse set of on-premises hardware boxes from different vendors' and away from 'stringing together multiple point-cloud solutions that only address specific network needs', toward one integrated provider it calls the Connectivity Cloud, and places Cloudflare as 'a leader in this Connectivity Cloud category'. The economics are unusual: idle capacity funds a free tier, the free tier buys global traffic scale, that scale makes Cloudflare a peering partner ISPs want, and peering cuts colocation and bandwidth cost - a loop the filing says 'become[s] even more powerful' as the network grows. Independent measurement confirms where that loop has already settled the market: W3Techs on 2026-09-17 shows an 85.0% reverse-proxy share and the largest authoritative-DNS footprint at 18.5% of all websites. Commercially the company ended 2025 with roughly 332,000 paying customers in more than 190 countries and 4,298 large customers, up from 2,756 two years earlier, with no customer above 10% of revenue. The contested half of the story is the growth half: the SASE platform competes with established cloud-security, email-security and SD-WAN vendors, and the developer platform competes for storage and compute against hyperscalers, markets where the 10-K's own risk factors concede rivals have greater name recognition, larger customer bases and 'more mature products and services developed for large customers'. The core is defended; the adjacencies are being fought for, and FY2025 gross margin at a nine-year low of 74.5% is the first visible cost of building GPU capacity for that fight. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. | Amkor is a back-end contractor; the 10-K says "We provide turnkey packaging and test services including wafer bump, wafer probe, wafer back-grind, package design, packaging, burn-in, system level and final test and drop shipment services." It also says "Our customers include most of the world's largest semiconductor companies." Advanced Products (flip chip, memory and wafer-level packages) were 82.8% of its $6,708M in 2025 net sales. The durable part of its position is scale and a multi-country footprint, which the filing calls "a key differentiator", backed by multi-month customer qualification and customer relationships it dates back "over the last five decades". On Arizona, the filing says: "Construction began in the second half of 2025, and we believe that this investment will strengthen our ability to serve customers seeking to regionalize their supply chains and will enhance our participation in U.S. semiconductor initiatives." Price caps the moat. The 10-K says "We expect downward pressure on average selling prices for our packaging and test services to continue in the future, and this pressure may intensify during downturns in business." It also says foundries "substantially larger than us" have expanded their operations to include packaging and test services. |
| Chain position | Cloudflare sits between end users and whatever hosts the application - origin data centre, public cloud or SaaS - so it is a control layer in front of infrastructure rather than infrastructure a workload runs on, which the 10-K argues is the point: customers 'concerned about being locked in to any one public cloud provider' want policy enforced by 'an independent and integrated services provider'. Two AI-era roles follow from that position. As a supplier, the filing describes 'ongoing deployment of graphics processing units (GPUs) across our global network of servers' behind Workers AI, Vectorize and AI Gateway, putting inference next to the user instead of in a region. As a gatekeeper, the application-services suite now exists in part to 'easily identify, block and control access from AI crawlers and AI agents and operators' and underpins announced efforts to let content creators monetise how those crawlers reach their work - which makes Cloudflare a toll point between AI model builders and the open web. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. | Back-end packaging and test step between wafer fabs and chip vendors. The 10-K says "the wafers that we receive from our customers are generally consigned to us", and Amkor serves IDMs, fabless companies, OEMs and contract foundries that outsource packaging and test. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm neutral Editorial prior, not backtested. |